Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Ovarian Neoplasms"" wg kryterium: Temat


Tytuł:
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
Autorzy:
Tavares V; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP), Pathology and Laboratory Medicine Department, Clinical Pathology (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal.; Faculty of Medicine, University of Porto, 4200-072 Porto, Portugal.; ICBAS-Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal.
Marques IS; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP), Pathology and Laboratory Medicine Department, Clinical Pathology (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal.; Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal.
Melo IG; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP), Pathology and Laboratory Medicine Department, Clinical Pathology (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal.; Faculty of Medicine, University of Porto, 4200-072 Porto, Portugal.
Assis J; Clinical Research Unit, Research Center of IPO Porto (CI-IPOP), (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal.
Pereira D; Oncology Department, Portuguese Institute of Oncology of Porto (IPOP), 4200-072 Porto, Portugal.
Medeiros R; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP), Pathology and Laboratory Medicine Department, Clinical Pathology (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal.; Faculty of Medicine, University of Porto, 4200-072 Porto, Portugal.; ICBAS-Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal.; Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal.; Research Department, Portuguese League Against Cancer (NRNorte), 4200-172 Porto, Portugal.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 03; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Ovarian Neoplasms*/therapy
Ovarian Neoplasms*/drug therapy
Genital Neoplasms, Female*
Humans ; Female ; Quality of Life ; Neoplasm Recurrence, Local ; Biomarkers
Czasopismo naukowe
Tytuł:
Childhood body fatness and the risk of epithelial ovarian cancer: A population-based case-control study in Montreal, Canada.
Autorzy:
L'Espérance K; Université de Montréal Hospital Research Centre (CRCHUM), 850, rue Saint-Denis, Montréal, Québec H2X 0A9, Canada; Department of Social and Preventive Medicine, Université de Montréal, 7101, avenue du Parc, Montréal, Québec H3N 1X9, Canada.
Abrahamowicz M; Centre for Outcomes Research and Evaluation and Division of Clinical Epidemiology, 1001, boulevard Décarie, Montréal, Québec H4A 3J1, Canada; Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine and Health Sciences, McGill University, 2001, avenue McGill College, Montréal, Québec H3A 1Y7, Canada.
O'Loughlin J; Université de Montréal Hospital Research Centre (CRCHUM), 850, rue Saint-Denis, Montréal, Québec H2X 0A9, Canada; Department of Social and Preventive Medicine, Université de Montréal, 7101, avenue du Parc, Montréal, Québec H3N 1X9, Canada.
Koushik A; Université de Montréal Hospital Research Centre (CRCHUM), 850, rue Saint-Denis, Montréal, Québec H2X 0A9, Canada; Department of Social and Preventive Medicine, Université de Montréal, 7101, avenue du Parc, Montréal, Québec H3N 1X9, Canada; Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences, McGill University, 5100 de Maisonneuve Blvd. West, Suite 720, Montréal, Québec H4A 3T2, Canada; St. Mary's Research Centre, 3830 Lacombe Ave, Montréal, Québec, H3T 1M5, Canada. Electronic address: .
Pokaż więcej
Źródło:
Preventive medicine [Prev Med] 2024 Jan; Vol. 178, pp. 107794. Date of Electronic Publication: 2023 Dec 10.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/epidemiology
Ovarian Neoplasms*/etiology
Ovarian Neoplasms*/pathology
Neoplasms, Glandular and Epithelial*/epidemiology
Neoplasms, Glandular and Epithelial*/etiology
Child ; Adult ; Humans ; Female ; Carcinoma, Ovarian Epithelial/epidemiology ; Carcinoma, Ovarian Epithelial/etiology ; Case-Control Studies ; Risk Factors
Czasopismo naukowe
Tytuł:
Pattern A endocervical adenocarcinomas with ovarian metastasis are indolent and molecularly distinct from destructively invasive adenocarcinomas.
Autorzy:
Neil AJ; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Li YY; Dana Farber Cancer Institute, Boston, MA, USA.
Hakam A; Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA.
Nucci MR; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Parra-Herran C; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło:
Histopathology [Histopathology] 2024 Jan; Vol. 84 (2), pp. 369-380. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article
MeSH Terms:
Uterine Cervical Neoplasms*/genetics
Uterine Cervical Neoplasms*/diagnosis
Papillomavirus Infections*/complications
Adenocarcinoma*/pathology
Adenocarcinoma in Situ*
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/secondary
Female ; Humans
Czasopismo naukowe
Tytuł:
Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.
Autorzy:
Zhu Y; Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Yang Q; Department of Pathology, Tangshan Cancer Hospital, Tangshan, China.
Liu K; Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Cao H; Department of Oncology, Chenzhou First People's Hospital, Chenzhou, China.
Zhu H; Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. .
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2024 Jan; Vol. 35 (1), pp. e2. Date of Electronic Publication: 2023 Jul 05.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Phthalazines*
Piperazines*
Humans ; Female ; Bevacizumab/therapeutic use ; Cost-Effectiveness Analysis ; Cost-Benefit Analysis ; Carcinoma, Ovarian Epithelial
Czasopismo naukowe
Tytuł:
HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Autorzy:
Ma S; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.; Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.
Wang J; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.
Cui Z; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.
Yang X; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.; Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.
Cui X; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.; Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.
Li X; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.; Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.
Zhao L; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China. .; Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China. .; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China. .; Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 16; Vol. 14 (1), pp. 3870. Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article
MeSH Terms:
Cisplatin*/pharmacology
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Humans ; Female ; Proto-Oncogene Proteins c-akt/metabolism ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Drug Resistance, Neoplasm/genetics ; Cell Line, Tumor ; DNA Repair ; Hypoxia ; Apoptosis/genetics ; Basic Helix-Loop-Helix Transcription Factors/metabolism ; Cell Proliferation ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Adult-type granulosa cell tumor associated with elevated luteinizing hormone: Two rare case reports.
Autorzy:
Wang Y; Department of Gynecology, The First Hospital of Hebei Medical University, 050030, Shijiazhuang, China.
Wang N; Department of Gynecology, The First Hospital of Hebei Medical University, 050030, Shijiazhuang, China.
Zhang X; Department of Gynecology, The First Hospital of Hebei Medical University, 050030, Shijiazhuang, China.
Fu Z; Department of Gynecology, The First Hospital of Hebei Medical University, 050030, Shijiazhuang, China.
Pang C; Department of Pathology, The First Hospital of Hebei Medical University, 050030, Shijiazhuang, China.
Zhang Y; Department of Gynecology, The Second Hospital of Hebei Medical University, 050004, Shijiazhuang, China.
Li X; Department of Gynecology, The First Hospital of Hebei Medical University, 050030, Shijiazhuang, China.
Pokaż więcej
Źródło:
Medicine [Medicine (Baltimore)] 2024 Feb 16; Vol. 103 (7), pp. e37069.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Granulosa Cell Tumor*/diagnosis
Granulosa Cell Tumor*/surgery
Granulosa Cell Tumor*/pathology
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/surgery
Ovarian Neoplasms*/metabolism
Adult ; Female ; Humans ; Luteinizing Hormone ; Amenorrhea/etiology ; Testosterone
Czasopismo naukowe
Tytuł:
Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Autorzy:
Li W; Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.
Huang L; Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.
Qi N; Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.
Zhang Q; Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China. .
Qin Z; Genetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China. .
Pokaż więcej
Źródło:
BMC genomics [BMC Genomics] 2024 Feb 16; Vol. 25 (1), pp. 183. Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article
MeSH Terms:
Cisplatin*/pharmacology
Cisplatin*/therapeutic use
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Humans ; Female ; Platinum/pharmacology ; Platinum/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Up-Regulation ; Calmodulin-Binding Proteins/genetics ; Calmodulin-Binding Proteins/therapeutic use ; Neoplasm Recurrence, Local ; Prognosis
Czasopismo naukowe
Tytuł:
Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
Autorzy:
Xia D; Department of Gynaecology and Obstetrics, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Xu X; Department of Gynaecology and Obstetrics, Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, China.; South China Normal University, Guangzhou, China.
Du P; Department of Gynaecology and Obstetrics, Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, China.
Pokaż więcej
Źródło:
International journal of cancer [Int J Cancer] 2024 Feb 15; Vol. 154 (4), pp. 762-763. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Letter
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Ovarian Epithelial ; Neoplasm Recurrence, Local/drug therapy ; Phthalazines/adverse effects
Opinia redakcyjna
Tytuł:
Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.
Autorzy:
Herzog C; European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria.; Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria.
Jones A; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Evans I; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Reisel D; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Olaitan A; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Doufekas K; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
MacDonald N; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Rådestad AF; Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Gemzell-Danielsson K; Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Zikan M; Department of Gynecology and Obstetrics, Charles University in Prague, First Faculty of Medicine and Hospital, Na Bulovce, Czech Republic.
Cibula D; Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University, Prague and, General University Hospital, Prague, Czech Republic.
Dostálek L; Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University, Prague and, General University Hospital, Prague, Czech Republic.
Paprotka T; GENEWIZ Germany GmbH, Bahnhofstraße, Germany.
Leimbach A; Eurofins Genomics Europe Sequencing GmbH, Konstanz, Germany.
Schmitt M; Eurofins Genomics Europe Sequencing GmbH, Konstanz, Germany.
Ryan A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Gentry-Maharaj A; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Apostolidou S; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Rosenthal AN; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Menon U; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Widschwendter M; European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria.; Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria.; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.; Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło:
International journal of cancer [Int J Cancer] 2024 Feb 15; Vol. 154 (4), pp. 679-691. Date of Electronic Publication: 2023 Oct 20.
Typ publikacji:
Journal Article
MeSH Terms:
DNA Methylation*
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/genetics
Humans ; Female ; Case-Control Studies ; Prospective Studies ; Early Detection of Cancer/methods ; Biomarkers, Tumor/genetics ; CA-125 Antigen ; Kruppel-Like Transcription Factors/genetics
Czasopismo naukowe
Tytuł:
Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
Autorzy:
Kim YN; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Joung JG; Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Korea.
Park E; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Kim JW; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Lee JB; Department of Clinical Epidemiology & Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, Korea.
Lim J; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Korea.; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea.
Kim S; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Choi CH; Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim HS; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Chung J; Geninus Inc., Seoul, Korea.
Kim BG; Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee JY; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
International journal of cancer [Int J Cancer] 2024 Feb 15; Vol. 154 (4), pp. 764-765. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Letter
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Ovarian Epithelial ; Neoplasm Recurrence, Local/drug therapy ; Phthalazines/adverse effects
Opinia redakcyjna
Tytuł:
Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data.
Autorzy:
You Y; Department of gynaecology, Shengjing Hospital of China Medical University, Shenyang, China.
Yang Q; Department of gynaecology, Shengjing Hospital of China Medical University, Shenyang, China. yangqing_.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 14; Vol. 24 (1), pp. 207. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/therapy
Humans ; Female ; Glycosylation ; Prognosis ; Protein Processing, Post-Translational ; Sequence Analysis, RNA ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.
Autorzy:
Liu Z; Department of Gynecology and Obstetrics, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, Liaoning Province, China.
Jing C; Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116000, Liaoning Province, China.
Kong F; Department of Gynecology and Obstetrics, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, Liaoning Province, China. .
Pokaż więcej
Źródło:
Journal of ovarian research [J Ovarian Res] 2024 Feb 12; Vol. 17 (1), pp. 39. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Ovarian Neoplasms*/therapy
Ovarian Neoplasms*/drug therapy
Female ; Humans ; Precision Medicine ; Carcinoma, Ovarian Epithelial/therapy ; Prognosis
Czasopismo naukowe
Tytuł:
Comprehensive analysis of single cell and bulk data develops a promising prognostic signature for improving immunotherapy responses in ovarian cancer.
Autorzy:
Ding H; Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Medical Key Laboratory for Prevention and Treatment of Malignant Gynecological Tumor, Henan Province, China.
Hu B; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Guo R; Medical Key Laboratory for Prevention and Treatment of Malignant Gynecological Tumor, Henan Province, China.; Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Feb 12; Vol. 19 (2), pp. e0298125. Date of Electronic Publication: 2024 Feb 12 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/therapy
Humans ; Female ; Prognosis ; Immunotherapy ; Nomograms ; Antigen Presentation
Czasopismo naukowe
Tytuł:
Metabolic-Related Gene Prognostic Index for Predicting Prognosis, Immunotherapy Response, and Candidate Drugs in Ovarian Cancer.
Autorzy:
Guo S; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China.
Liu Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Sun Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Zhou H; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Gao Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Wang P; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Zhi H; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Zhang Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Gan J; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Ning S; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Pokaż więcej
Źródło:
Journal of chemical information and modeling [J Chem Inf Model] 2024 Feb 12; Vol. 64 (3), pp. 1066-1080. Date of Electronic Publication: 2024 Jan 18.
Typ publikacji:
Journal Article
MeSH Terms:
Immunotherapy*
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Humans ; Female ; Prognosis ; Metabolic Reprogramming ; Mutation
Czasopismo naukowe
Tytuł:
CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Autorzy:
Luo X; Department of Gynecological Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.
Mo J; Institute of Reproduction and Development, Fudan University, Shanghai, 200011, China.
Zhang M; Department of Gynecological Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.
Huang W; Department of Gynecological Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.
Bao Y; Department of Gynecological Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.
Zou R; Department of Gynecological Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.
Yao L; Department of Gynecological Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.
Yuan L; Department of Gynecological Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2024 Feb 06; Vol. 22 (1), pp. 44. Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Neoplasms, Glandular and Epithelial*/genetics
Humans ; Female ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/pathology ; Prognosis ; CD47 Antigen/genetics ; Biomarkers, Tumor/genetics ; Kaplan-Meier Estimate ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Autorzy:
Wei X; Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.
Sun L; Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.
Slade E; National Institute for Health and Care Excellence, London, United Kingdom.
Fierheller CT; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.
Oxley S; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.; Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom.
Kalra A; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.; Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom.
Sia J; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.; Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom.
Sideris M; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.; Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom.
McCluggage WG; Department of Pathology, Belfast Health & Social Care Trust, Royal Victoria Hospital, Belfast, United Kingdom.
Bromham N; National Institute for Health and Care Excellence, London, United Kingdom.
Dworzynski K; National Institute for Health and Care Excellence, London, United Kingdom.
Rosenthal AN; Department of Gynaecology, University College London Hospitals NHS Foundation trust, London, United Kingdom.; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, United Kingdom.
Brentnall A; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.
Duffy S; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.
Evans DG; Manchester Centre for Genomic Medicine, Division of Evolution, Infection and Genomic Sciences, University of Manchester, MAHSC, Manchester, United Kingdom.
Yang L; School of Public Health, Peking University, Beijing, China.
Legood R; Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.
Manchanda R; Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom.; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.; Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom.; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, United Kingdom.
Pokaż więcej
Źródło:
JAMA network open [JAMA Netw Open] 2024 Feb 05; Vol. 7 (2), pp. e2355324. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Breast Neoplasms*/prevention & control
Breast Neoplasms*/pathology
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/prevention & control
Ovarian Neoplasms*/surgery
Female ; Humans ; Adult ; Middle Aged ; Cost-Benefit Analysis ; Mastectomy ; Salpingo-oophorectomy
Czasopismo naukowe
Tytuł:
Effects of rosmarinic acid and doxorubicine on an ovarian adenocarsinoma cell line (OVCAR3) via the EGFR pathway.
Autorzy:
Sarı U; Umut Sarı Clinic - Department of Gynecology and Obstetrics - Istanbul, Turkey.
Zaman F; Diyarlife Hospital - Department of Obstetrics and Gynecology - Diyarbakır, Turkey.
Pokaż więcej
Źródło:
Acta cirurgica brasileira [Acta Cir Bras] 2024 Feb 05; Vol. 39, pp. e390524. Date of Electronic Publication: 2024 Feb 05 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/pathology
Adenocarcinoma*/pathology
Humans ; Female ; Rosmarinic Acid ; Apoptosis ; Cell Line, Tumor ; Doxorubicin/pharmacology ; ErbB Receptors/metabolism ; ErbB Receptors/pharmacology ; Cell Proliferation
Czasopismo naukowe
Tytuł:
SETDB1 promotes progression through upregulation of SF3B4 expression and regulates the immunity in ovarian cancer.
Autorzy:
Yang H; Department of Obstetrics and Gynecology, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266000, Shandong Province, China.
Sui L; Department of Gynecological Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266000, Shandong, China.
Cai C; Department of Obstetrics and Gynecology, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266000, Shandong Province, China.
Chu H; Department of Obstetrics and Gynecology, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266000, Shandong Province, China.
Diao Y; Department of Obstetrics and Gynecology, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266000, Shandong Province, China. .
Pokaż więcej
Źródło:
Journal of ovarian research [J Ovarian Res] 2024 Feb 05; Vol. 17 (1), pp. 34. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Histone-Lysine N-Methyltransferase*/genetics
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Humans ; Female ; Up-Regulation ; Prognosis ; Cell Proliferation/genetics ; Cell Line, Tumor ; Tumor Microenvironment ; RNA Splicing Factors/genetics
Czasopismo naukowe
Tytuł:
The management of uterine tumor resembling an ovarian sex cord tumor (UTROSCT): case series and literature review.
Autorzy:
Lin J; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Liu L; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Wang L; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Ma N; Department of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Zhang K; Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, China.
Xie N; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Yu H; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Deng S; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Sun Y; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2024 Feb 03; Vol. 22 (1), pp. 42. Date of Electronic Publication: 2024 Feb 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Uterine Neoplasms*/diagnosis
Uterine Neoplasms*/surgery
Endometrial Neoplasms*/surgery
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/surgery
Humans ; Female ; Middle Aged ; Retrospective Studies ; Hysterectomy
Czasopismo naukowe
Tytuł:
Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
Autorzy:
Wenk D; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto M5G 1L7, Ontario, Canada.
Khan S; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto M5G 1L7, Ontario, Canada.
Ignatchenko V; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto M5G 1L7, Ontario, Canada.
May T; Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto M5G 2C4, Ontario, Canada.; Department of Obstetrics and Gynaecology, University of Toronto, 123 Edward Street, Toronto M5G 1E2, Ontario, Canada.
Bernardini MQ; Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto M5G 2C4, Ontario, Canada.; Department of Obstetrics and Gynaecology, University of Toronto, 123 Edward Street, Toronto M5G 1E2, Ontario, Canada.
Kislinger T; Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto M5G 1L7, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto M5G 1L7, Ontario, Canada.
Pokaż więcej
Źródło:
Journal of proteome research [J Proteome Res] 2024 Feb 02; Vol. 23 (2), pp. 749-759. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/metabolism
Cystadenocarcinoma, Serous*/pathology
Female ; Humans ; Biomarkers, Tumor ; Neoplasm Recurrence, Local ; Glycoproteins ; Mass Spectrometry ; Fibrinogen ; Latent TGF-beta Binding Proteins
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies